Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosphenytoin for prevention of post-neurosurgical seizures
ChiCTR2400090511Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fosphenytoin in postoperative seizure and seizure, sponsored by West China Hospital of Sichuan University. Primary endpoint: Incidence of seizures within 7 days after operation. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
fosphenytoin
03
Conditions
postoperative seizureseizure
Beyond the preview
Go deeper on ChiCTR2400090511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090511.